[1] Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol, 2017,17:559-572.
[2] Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol, 2014,32:659-702.
[3] Han KQ, He XQ, Ma MY, et al. Inflammatory micro-environment and expression of chemokines in hepatocellular carcinoma. World J Gastroenterol, 2015,21:4864-4874.
[4] Zhang X, Wan JX, Ke ZP, et al. Tmem88, CCL14 and clec3b as prognostic biomarkers for prognosis and palindromia of human hepatocellular carcinoma. Tumour Biol, 2017,39:1010428317708900.
[5] Zhang H, He G, Kong Y, et al. Tumour-activated liver stromal cells regulate myeloid-derived suppressor cells accumulation in the liver. Clin Exp Immunol, 2017,188:96-108.
[6] Li L, Zhu YH, Li Y, et al. Identification of chemokine CXCL10 in tumor microenvironment by antibody array as a prognostic marker in hepatocellular carcinoma. Neoplasma, 2017,64:778-786.
[7] Kaemmerer D, Schindler R, Mussbach F, et al. Somatostatin and CXCL4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: Tumor capillaries as promising targets. BMC cancer, 2017,17:896.
[8] Zhou SL, Zhou ZJ, Hu ZQ, et al. Cxcr2/cxcl5 axis contributes to epithelial mesenchymal transition of hcc cells through activating pi3k/akt/gsk-3 beta/snail signaling. Cancer letters, 2015,358:124-135.
[9] Hu B, Fan H, Lv X, et al. Prognostic significance of CXCL5 expression in cancer patients: A meta-analysis. Cancer Cell Int, 2018,18.
[10] Subat S, Mogushi K, Yasen M, et al. Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma. J Cancer Res Clin Oncol, 2019,145:675-684.
[11] Wu Y, Tian L, Xu Y, et al. CXCR7 silencing inhibits the migration and invasion of human tumor endothelial cells derived from hepatocellular carcinoma by suppressing stat3. Mol Med Rep, 2018,18:1644-1650.
[12] Gao Q, Zhao YJ, Wang XY, et al. Cxcr6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res, 2012,72:3546-3556.
[13] 刘业六,钱海鑫,张荻,等. 趋化因子受体6/趋化因子20生物轴在肝癌组织中的表达及临床意义. 中华消化杂志, 2014,34:256-259.
[14] Barashi N, Weiss ID, Wald O, et al. Inflammation-induced hepatocellular carcinoma is dependent on CCL5 in mice. Hepatology, 2013,58:1021-1030.
[15] Sasaki R, Devhare PB, Steele R, et al. Hepatitis c virus-induced CCL5 secretion from macrophages activates hepatic stellate cells. Hepatology, 2017,66:746-757.
[16] Qin CJ, Zhao LH, Zhou X, et al. Inhibition of dipeptidyl peptidase iv prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2. Cancer Lett, 2018,420:26-37.
[17] Zhu Y, Gao XM, Yang J, et al. C-c chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma. Cancer Sci, 2018,109:710-723.
[18] Zhou SL, Zhou ZJ, Hu ZQ, et al. Tumor-associated neutrophils recruit macrophages and t-regulatory cells to promote progre-ssion of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology, 2016,150:1646-1658 e1617.
[19] Chanmee T, Ontong P, Konno K, et al. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers, 2014,6:1670-1690.
[20] Wu SD, Ma YS, Fang Y, et al. Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treat Rev, 2012,38:218-225.
[21] Liu LZ, Zhang Z, Zheng BH, et al. CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma. Hepatology, 2019,69:143-159.
[22] Tan HW, Wang SY, Zhao LD. A tumour-promoting role of TH9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways. Clin Exp Pharmacol Physiol, 2017,44:213-221.
[23] Shi JY, Duan M, Sun QM, et al. Naive treg-like CCR7(+) mononuclear cells indicate unfavorable prognosis in hepa-tocellular carcinoma. Tumor Biol, 2016,37(7):9909-9917.
[24] Liepelt A, Tacke F. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases. Am J Physiol Gastrointest Liver Physiol, 2016,311:G203-G209.
[25] Graham GJ. D6 and the atypical chemokine receptor family: novel regulators of immune and inflammatory processes. Eur J Immunol, 2009,39:342-351.
[26] Ulvmar MH, Hub E, Rot A. Atypical chemokine receptors. Exp Cell Res, 2011,317:556-568.
[27] Shi JY, Yang LX, Wang ZC, et al. CC chemokine receptor-like 1 functions as a tumour suppressor by impairing CCR7-related chemotaxis in hepatocellular carcinoma. J Pathol, 2015,235:546-558.
[28] L′Hermitte A, Pham S, Cadoux M, et al. Lect2 controls inflammatory monocytes to constrain the growth and progression of hepatocellular carcinoma. Hepatology, 2019,69:160-178. |
